Market Access News | pharmaphorum

News

NICE rejects Novartis’ migraine prevention drug Aimovig

Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.

News

Novartis' sickle cell drug gets Breakthrough Therapy designa...

The FDA has granted Breakthrough Therapy designation to Novartis' crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with

News

NICE broadens approval for AstraZeneca’s severe asthma drug

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for the drug’s use and giving

Market Access

Trump's war on drug pricing looks set to continue

Shrugging off warnings from president Donald Trump, pharma companies have announced US price hikes on more than 250 prescription drugs for 2019.

News

Praluent not worth the price, finds study

Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed.

News

Conceptual image of a head with cog gears as brain.

BioXcel's agitation drug gets FDA Fast Track

The FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting from neurological and psychiatric disorders like Alzheimer's and schizo

NICE rejects Novartis’ migraine prevention drug Aimovig

Novartis' sickle cell drug gets Breakthrough Therapy designa...

NICE broadens approval for AstraZeneca’s severe asthma drug

Trump's war on drug pricing looks set to continue

Praluent not worth the price, finds study

BioXcel's agitation drug gets FDA Fast Track

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks